Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-1123

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-1123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901123)

Label for Divalproex Sodium 250 mg delayed-release tablets, oral use, manufactured by A-S Medication Solutions. The label indicates a package of 30 coated, delayed-release tablets with the product number 6114-0 and NDC 50090-1123-0. Storage instructions specify 68-77 degrees Fahrenheit.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart labeled Figure 1 showing percentage results from two studies comparing PBO (placebo) with DVPX (Divalproex Sodium). Study 1 (YMRS) shows 26% for placebo and 60% for DVPX. Study 2 (MRS) shows 29% for placebo and 58% for DVPX. The y-axis is labeled with percentages from 0% to 70%.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Figure 2 is a cumulative percentage graph comparing % reduction in CPS (clinical parameter scale) rate between Divalproex Sodium (DVPX) and placebo groups. The x-axis displays % of patients from 100 to 0, while the y-axis shows % reduction in CPS rate from -100% to 100%, indicating worsening to improvement. Two curves represent patient response distributions for DVPX (solid line) and placebo (dashed line).*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A line chart labeled Figure 3 showing the percentage reduction in CPS (Clinical Parameter Score) rate on the vertical axis and the percentage of patients on the horizontal axis. Two lines are plotted: one for High Dose (solid line) and one for Low Dose (dashed line). The vertical axis has directional labels indicating improvement upward and worsening downward, with a zero line denoting no change.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between Placebo and Divalproex Sodium (DVPX) groups across two studies. Study 1 shows higher migraine rates for Placebo versus DVPX, and Study 2 also shows higher migraine rates for Placebo compared to DVPX, with both DVPX groups having reduced rates.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of divalproex sodium, showing a polymeric form with valproate groups linked via a sodium ion. The structure illustrates the arrangement of valproic acid molecules complexed with sodium, characteristic of divalproex sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.